<DOC>
	<DOC>NCT00575913</DOC>
	<brief_summary>To assess, under daily practice conditions, the safety profile and the efficacy of a new formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).</brief_summary>
	<brief_title>Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Prostatic Diseases</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Ambulatory patients suffering from lower urinary tract symptoms suggestive of BPH. Patients requiring BPH surgery immediately or within the 12 following months: Acute renal obstruction Chronic renal obstruction Chronic renal failure from BPH Bladder stone Recurrent urinary tract infection Other bladder pathology such as cancer of the bladder, bladder bidiverticulum (big size) Hematuria from BPH Patients whose urinary symptoms are satisfactorily controlled on other BPH medication ( alphablockers or 5 alphareductase) Patients previously not improved by an alpha1blocker treatment Known hypersensitivity to alfuzosin History of postural hypotension or syncope Combination with other alpha1blockers Hepatic enzyme (SGOT or/and SGPT ) &gt; 1.5 Upper Normal Limit Unstable angina pectoris Severe concomitant condition threatening life. Patients who had failed treatment with finasteride (Proscar) Patients with neuropathic bladder. Patients with history of previous surgery for BPH Patients with high risk for prostate cancer based on the clinical judgement of the investigator The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>